The proposed transaction values the company at approximately $137.99 per share, a sharp climb from Thursday’s closing price of $90.38. While neither company has officially confirmed the agreement, sources familiar with the matter suggest an announcement could arrive as early as Monday. This acquisition would place Apogee’s specialized biotechnology portfolio directly under the control of the pharmaceutical giant, marking a major consolidation move within the sector.
In section Market Quotes
AbbVie Eyes $10.9 Billion Acquisition of Apogee Therapeutics
A potential $10.9 billion cash deal is driving Apogee Therapeutics shares to a 53% surge in premarket trading. According to reports, AbbVie is closing in on the acquisition of the Waltham-based biotechnology firm, signaling a significant expansion of its clinical-stage pipeline at a 60% premium over recent market valuations.
Comments (0)
No comments yet. Be the first!